Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com to Unlock Their Full Potential

Boehringer IngelheimBoehringer Ingelheim has announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.

"Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas," said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. "This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compounds with scientists around the world, we will advance scientific research and expect to spark discoveries that will lead to safe and effective new medicines for patients."

The molecules on opnMe.com are divided in two groups, offered under different conditions:

  • The majority of molecules are offered without entering into intellectual property discussions via a simple shopping cart system.
  • For selected molecules a crowdsourcing option offers the opportunity to initiate joint research projects. Scientists interested in such molecules for collaboration are invited to submit a research proposal. If the proposal is selected, the science will be developed together with Boehringer Ingelheim scientists.

This launch is part of Boehringer Ingelheim’s ongoing mission to further scientific research and medical progress through collaboration and innovation. Other initiatives include Research Beyond Borders and the Boehringer Ingelheim Venture Fund. They are part of the company's long-standing and continuing work in core therapeutic areas of Cardiometabolic Diseases, Respiratory Diseases, Oncology, CNS Diseases and Immunology.

Clive Wood adds, "I invite interested scientists worldwide to visit opnMe.com to access our molecules. We will measure the success of this initiative in terms of new experiments, publications and relationships forged. This approach to open innovation reflects our determination to break down barriers to the advancement of biomedical research and bring breakthrough medicines to patients."

For further information, please visit:
https://opnme.com

About Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

Most Popular Now

Open Call SC1-DTH-01-2019: Big Data and …

Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of...

Cerner Selected for NHS Framework to Sup…

Integrated Care Systems (ICS) and Sustainability and Transformation Partnerships (STPs) aim to deliver the best possible quality of health and care, shift to value-based care and proactively improve outcomes for...

Brainlab and Magic Leap Partner in Digit…

Brainlab has announced a strategic development partnership with Florida-based Magic Leap, a developer of proprietary spatial computing solutions that help users enrich their real world experience by integrating digital content...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites...

Whole-Brain Connectome Maps Teach Artifi…

Medical University of South Carolina (MUSC) neurologists have developed a new method based on artificial intelligence that may eventually help both patients and doctors weigh the pros and cons of...

Oxehealth Secures World-First Accreditat…

The British Standards Institute (BSI) has accredited Oxehealth's vital signs measurement software as a Class IIa medical device in Europe. This is the first time that software enabling a digital...

MEDICA 2018: The Starting Block for Many…

12 - 15 November 2018, Düsseldorf, Germany. MEDICA, the world’s leading medical trade fair in Düsseldorf which attracts over 5,000 exhibitors from around 70 countries, is becoming an even bigger hotspot...

MEDICA 2018 Presents the Future of Medic…

12 - 15 November 2018, Düsseldorf, Germany. Artificial intelligence, Big Data or IoT (Internet of Things) - we would be hard pressed to find a sector that doesn’t have these terms...

Artificial Intelligence for Health: ITU …

The ITU Focus Group on 'AI for Health' (FG-AI4H), created in collaboration with the World Health Organization (WHO), has issued a Call for Proposals to identify compelling use cases of...

Siemens Healthineers and STORZ MEDICAL P…

On the occasion of the 70th annual congress of the German Society for Urology, DGU, Siemens Healthineers and STORZ MEDICAL have announced plans to enter into a sales partnership agreement...

Spinal Cord Stimulation, Physical Therap…

Spinal cord stimulation and physical therapy have helped a man paralyzed since 2013 regain his ability to stand and walk with assistance. The results, achieved in a research collaboration between...

Sandoz Healthcare Access Challenge #Sand…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators...